Personalis shares rose after the company received Medicare coverage for its NeXT Personal molecular residual disease test for surveillance of patients with Stage I to III non-small cell lung cancer.

Investing.com -- Personalis Inc (NASDAQ:PSNL) stock jumped 9.3% Tuesday after the precision oncology company announced ...

Circulating tumor DNA may be an effective biomarker for stratifying patients with small cell lung cancer who would benefit from more stringent follow-ups and clinical trial participation.Patients who ...

Personalis, Inc. , a leader in advanced genomics for precision oncology, today announced Medicare coverage for the company's NeXT Personal molecular residual disease (MRD) test for surveillance of ...

NCCN's newly updated NSCLC guidelines add sevabertinib as a treatment option and datopotamab deruxtecan-dlink a potential preferred option.

Personalis, Inc. PSNL stock is up in Tuesday’s premarket session after the company received Medicare coverage for its NeXT Personal molecular residual disease test for lung cancer surveillance. This ...

Medicare will reimburse the company’s NeXT Personal molecular residual disease (MRD) test when used to monitor patients with ...

Lung cancer remains one of the leading causes of cancer-related deaths globally and in India; yet it is also one of the most misunderstood cancers. Public perception has long framed it as a ...

Throughout a person's lifetime, the cells lining the respiratory tract are exposed to inhaled pollutants, including cigarette smoke. These exposures can cause molecular changes that disrupt normal ...

Lung cancer is one of the leading causes of cancer-related death in our country, especially due to widespread myths and the lack of awareness.

Survivors of non-small cell lung cancer are at risk for both second primary lung cancers as well as non-lung secondary ...